1Follath F,Cleland JG,Just H, et al. Efficacy and safety ofintravenous levosimendan compared wirh dobutamine in severelow-output heart failure (the LIDO study) : a randomizeddouble-blind trial [J]. Lancet, 2002,360(9328) : 196-202.
2Moiseyev VS. Poder P, Andrejevs N, et al. Safety and efficacyof a novel calcium sensitizer.levosimendan, in patients with leftventricular failure due to an acute myocardial infarction. Arandomized,placebo-controlled,double~blind study (RUSSLAN)[J]. Eur Heart J,2002,23(18) : 1422-1432.
3Cleland JG,Ghosh J,Freemantle N,et al. Clinical trials updateand cumulative meta-analyses from the American College ofCardiology: WATCH, SCD-HeFT, DINAMIT, CASINO,INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchroni-sation therapy in heart failure [J], Eur J Heart Fail, 2004,6(4):501-508.
4Dec GW. Acute decompensated heart failure: the shrinking roleof inotropic therapy[J]. J Am Coll Cardiol,2005,46(1) : 65-67.
1[2]Kopustinskiene DM,Pollesello P,Saris NE.Potassium-specific effects of levosimendan on heart mitochondria[J].Biochem Pharmacol, 2004,68(5):807.
2[3]Rump AF,Acar D,Rosen R,et al. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts[J].Pharmacol Toxicol, 1994,74( 4-5 ) :244.
3[4]Yokoshiki H,Katsube Y,Sunagawa M,et al. Levosimendan,a novel Ca2+sensitizer,activates the glibenclamide-sensitive K+channel in rat arterial myocytes [J].Eur J Pharmacol,1997,333(2-3):249.
4[5]Sundberg-S, Lilleberg-J, Nieminen-MS, et al. Hemodynamic an d neurohumoral effects of Levosimendan, a new calcium sensitizer,at rest and during exercise in healthy men [J].AmericanJournal-of-Cardiology, 1995,75(15): 1061.
5[6]Antila S,Huuskonen H,Nevalainen T,et al. Site dependent bioavailability and metabolism of levosimendan in dogs[J]. Eur J Pharm Sci,1999,9(1):85.
6[7]Antila S,Kivikko M,Lehtonen L,et al.Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan[J].Br J Clin Pharmacol, 2004,57(4): 412.
7[8]Poder P,Eha J,Sundberg S,et al. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure:a dosing interval study[J].J Clin Pharmacol,2004,44( 10 ) :1143.
8[9]Turanlahti M,Boldt T,Palkama T,et al.Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery [J].Pediatr Crit Care Med,2004,5( 5 ):457.
10PAPP JG. Introduction: positive inotropy by calcium sensitization- an evolving approach for the treatment of end-stage heart failure[J]. Am J Cardiol, 1999, 83(12B):1-3.
3Mebazaa A,Nieminen M S,Packer M,et al.Levosimendan vs dobutamine for patients with acute decompensated heart failure[J].JAMA:the journal of the American Medical Association,2007,297(17):1883-1891.
